The American people deserve the truth. FDA, do you remember Covaxin? The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop, while you were fast-tracking mRNA boosters based on trials conducted on just 8 mice? You urged the company to seek approval through a U.S. BLA trial, and they did—spending over $100 million on a massive Phase 3 trial that yielded top-line data showing broad protection against all variants of concern. Yet, despite this, you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why? Because just months after those results were published, you changed the rules to block any vaccine built on the original virus. This effectively killed the market for traditional vaccines based on the whole coronavirus. Meanwhile, you rolled out the next set of mRNA boosters, designed to mimic just a tiny piece of the spike protein on a virus that’s famously studied for its high mutation rates. It’s been four long years, and you still haven’t approved any competitor vaccines. The government collects royalties from mRNA sales, with companies like Moderna paying over $400 million in a single year. But those profits wouldn’t roll in from a traditional vaccine sale, would they? How has this financial entanglement influenced your decision-making during the pandemic? Your job is to serve the public—to prioritize science and protect the American people. But you’ve failed in that duty. Instead, you’ve used taxpayer dollars to accelerate only the development of “vaccines” that you own patents on, blocking all competitor vaccines for over four years. Do you really think the American people will trust that this next round of mRNA boosters will finally work, after six previous rounds failed to deliver? Your actions have severely damaged your credibility. Government entities should never receive kickbacks from the sales of drugs they’re responsible for approving. This is an egregious conflict of interest, and we’re living with the consequences. The amount of blood on your hands is staggering. Next-generation vaccines that have been proven to stop transmission are approved overseas, yet Americans have no choice but to take this mRNA snake oil. This is the biggest scam our country has ever seen. It’s time for real journalism to uncover the truth. There must be accountability, and the American people deserve to know who the main perpetrators are. Rest in peace to all those lost in this pandemic due to this corruption.

$OCGN The biggest question investors have now is: How many people are actually going to travel to the Bahamas and get OCU400? No one knows yet, but we can get a rough idea of the potential private pay market. At $2M per treatment, I’m not going to pretend someone worth $2M is likely to spend every penny they have to save their vision. With financing, payment plans, family money, etc that absolutely could happen, but let’s be conservative and only count families with access to $5M+ in investable assets. Capgemini’s latest wealth data shows 2.6M people worldwide have $5M+ in investable assets. Since the person with RP doesn’t have to be the millionaire, could be their parent, spouse, child, etc, let’s use a small 3 person immediate family assumption. That’s roughly 0.095% of the world’s population within that $5M+ family wealth pool. Now apply that percentage to the 1.6M people worldwide living with RP. You get: 1,500 potential private pay OCU400 patients. At $2M each, that’s: $3 BILLION in treatment sales! Now Ocugen doesn’t need anything remotely close to the entire potential market. Capture just 10%? That’s only around 150 patients. 150 × $2M = $300M in gross treatment sales. That’s 150 people out of 1.6M total… And this model completely ignores anyone worth under $5M, financing, insurance, government funding, charities, larger families pooling money together, etc. Nobody knows how many will show up in the Bahamas. But when you run the numbers, it sure doesn’t take much to become very meaningful. 🍻

$OCGN enjoy the absurdly stupid discount, will be harder to undervalue once the sales start rolling in soon. 💸 🏦

With You

$OCGN since mass confusion has go figure muddied what is arguably the most significant news in companies history. Ocugen I expect will clarify things soon. In the meantime, I decided to break down the news and model the opportunity using real examples for everyone. 🍻

$OCGN We are getting approved in the Bahamas, in 90 days we can start seeing commercial sales. LFG!!!!!!!!!!! Congrats bulls major revenue incoming! 🍻 🐂 ir.ocugen.com/news-releases/…

$OCGN couldn’t imagine having to get up to 12 eye injections a year. With OCU410 being a one and done therapy it be hard to imagine anyone not switching, then add the fact it’s twice the efficacy, psh game over they’re gonna have the whole market to themselves. 🍻

New track Ghost Code and lyric video. 🍻 youtu.be/uKAixOTcQNM?is=x3BR…

$OCGN The market saw headlines and reacted severely to information that doesn’t actually say anything at all. Ocugen was just at conferences, major funds are going to give their ratings and analysis. Their conclusion of the news will be exactly what I’ve laid out in my posts, that the news was meaningless, so their PT’s will remain unchanged. Ocugen dropped 26% off essentially nothing at all. So what happens when the market is soon to hear about that overreaction from credible sources? That 34.7% in potential gains it represents is going to be pretty hard to ignore imo. 🍻

Farmers Market 👨‍🌾 on.soundcloud.com/3Tn47tk1J9…

$OCGN Farmer pro tip: understand the science, then take advantage of the emotionally stupid. 🍻🐂

$OCGN sure and given what the DMC said it makes perfect sense. OCU410ST interim is pretty simple. Baseline lesion size is the driver of Stargardt progression. Larger lesions grow 2.7x faster than smaller lesions. The interim only looked at 26 patients, and the DMC said there was a baseline lesion size imbalance between the groups. That imbalance is not present in the full study population. The data skew in the interim was due to this imbalance and why they recommended to continue instead of ending and will look at the full 8 month dataset that won’t have the imbalance. Phase 1 showed OCU410ST slowed lesion growth by 52% at 6 months and 54% at 12 months, plus a 116% relative reduction in EZ loss. So with treated patients in that first 26 having larger lesions, they were naturally expected to progress much faster. Even with the same 54% treatment effect from Phase 1: 2.7 × 0.46 = 1.24 Meaning the treated group could look about 24% worse on raw lesion growth while the drug was actually cutting progression by more than half. 8 month data will show us pure results of the drug.